CSL

Navigating Uncertainty in the Biopharma Market

Biopharma companies are facing funding challenges in 2023 as interest rates rise and investors are becoming more risk adverse. There is hope on the horizon, say some analysts, while others project a prolonged slump due to inflation and global instability. Established pharmaceutical companies are often seen as safer investments, with larger developers expected to perform well in 2023, especially if litigation threats against drugs like Zantac disappear. However, concerns about revenue gaps continue for big companies like GSK and Sanofi, and their strategy and leadership will be closely monitored in the coming months.

CSL Close to Finally Taking Control of Vifor

Australian biopharma CSL said this week it has received all the regulatory clearance required to take over Switzerland’s Vifor. The acquisition announced in December 2021 temporarily stalled in May 2022.

CSL Takes Vifor Pharma for $11.7 Billion

After days of speculation, it’s now official. Australian biopharmaceuticals manufacturer CSL has grabbed for and won the hand of Swiss Vifor Pharma. The boards of both companies have unanimously approved the $11.7 billion public tender offer, which looks certain to be accepted by Vifor’s shareholders. Its largest, Patinex, with 23%, has already agreed to tender.

Grifols Nears Over $3 Billion Deal For Talecris